Construction and Characterization of a CTLA-4-Targeted scFv-Melittin Fusion Protein as a Potential Immunosuppressive Agent for Organ Transplant

Cell Biochemistry and Biophysics

Volumn 67, Issue 3, 2013, Pages 1067-1074

  Jin, Hailong ^a   Li, Congran ^a   Li, Ding ^b   Cai, Ming ^a   Li, Zhouli ^a   Wang, Shuang ^a   Hong, Xin ^a   Shi, Bingyi ^a  

^a 309TH HOSPITAL OF PLA   (China)

^b No 261 Hospital of PLA   (China)

Author keywords

Anti CTLA 4 scFv melittin; Immunosuppressant; Immunotoxin

Indexed keywords

ESCHERICHIA COLI;

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; MELITTIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; ESCHERICHIA COLI; GENETICS; HUMAN; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; CELL SURVIVAL; CTLA-4 ANTIGEN; ESCHERICHIA COLI; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; JURKAT CELLS; MELITTEN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORGAN TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 84888370016     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9605-9     Document Type: Article

References (26)

1. Stemer, G., & Lemmens-Gruber, R. (2010). Clinical pharmacy services and solid organ transplantation: a literature review. Pharmacy World & Science, 32, 7-18.
2. Sigal, L. H. (2012). Basic science for the clinician 55: CTLA-4. Journal of Clinical Rheumatology, 18, 155-158.
3. Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010). Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proceedings of the National Academy of Sciences, 107, 1524-1528.
4. Salama, April K. S., & Stephen Hodi, F. (2011). Cytotoxic T-Lymphocyte -Associated Antigen-4. Clinical Cancer Research, 17, 4622-4628.
5. Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002). CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunology, 3, 611-618.
6. Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., et al. (2006). Reversal of the TCR stop signal by CTLA-4. Science, 313, 1972-1975.
7. Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., et al. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of Clinical Oncology, 29, 2904-2909.
8. Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70, 5213-5219.
9. Habermann, E. (1972). Bee and wasp venoms the biochemistry and pharmacology of their peptides and enzymes are reviewed. Science, 177, 314-322.
10. Raghuraman, H., & Chattopadhyay, A. (2007). Melittin: a membrane-active peptide with diverse functions. Bioscience Reports, 27, 189-223.
11. Dempsey, C. E. (1990). The actions of melittin on membranes. Biochimica et Biophysica Acta, 1031, 143-161.
12. Son, D. J., Lee, J. W., Lee, Y. H., Song, H. S., Lee, C. K., & Hong, J. T. (2007). Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacology & Therapeutics, 115, 246-270.
13. Readett, DRJ., Jungnelius, JUB., Gomeznovarro, J., Hanson, D., Krieg, AM. (2007). Anti-CTLA-4 antibody and CpG-Motif-contanting synthetic oligodeoxynucleotide combination therapy for cancer treatment. WO 2007/008463 A2 [P], 1-18.
14. Zhao, Y. H., Bai, B. Y., Liu, A. S., Gao, X. Y., & Lin, J. R. (2008). Gene expression and structure-activity relationship of melittin analogues. Journal of South China University of Technology (Natural Science)., 12, 116-120.
15. Nelson, M. D., & Fitch, D. H. (2011). Overlap extension PCR: an efficient method for transgene construction. Methods in Molecular Biology, 772, 459-470.
16. Pistillo, M. P., Tazzari, P. L., Palmisano, G. L., Pierri, I., Bolognesi, A., Ferlito, F., et al. (2003). CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood, 101, 202-209.
17. Coelho, T., Tredger, M., & Dhawan, A. (2012). Current status of immunosuppressive agents for solid organ transplantation in children. Pediatric Transplantation, 16, 106-122.
18. Rudd, C. E., Taylor, A., & Schneider, H. (2009). CD28 and CTLA-4 coreceptor expression and signal transduction. Immunology Reviews, 229, 12-26.
19. Bolognesi, A., Polito, L., Tazzari, P., Lemoli, R. M., Lubelli, C., Fogli, M., et al. (2000). In vitro anti-tumor activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. British Journal of Haematology, 110, 351-361.
20. Weetall, M., Digan, M. E., Hugo, R., Mathew, S., Hopf, C., Tart-Risher, N., et al. (2002). T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3 epsilon transgenic mice. Transplantation, 73, 1658-1666.
21. Asiedu, C. K., Goodwin, K. J., Balgansuren, G., Jenkins, S. M., Le Bas-Bernardet, S., Jargal, U., et al. (2005). Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. Journal of Immunology, 175, 8060-8068.
22. Tazzari, P. L., Polito, L., Bolognesi, A., Pistillo, M. P., Capanni, P., Palmisano, G. L., et al. (2001). Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. Journal of Immunology, 167, 4222-4229.
23. Pistillo, M. P., Tazzari, P. L., Ellis, J. H., & Ferrara, G. B. (2000). Molecular characterization and applications of recombinant scFv antibodies to CD 152 co-stimulatory molecule. Tissue Antigens, 55, 229-238.
24. Zeng, L., Wan, L., Chen, L., Li, S., Lu, Y., Huang, Q., et al. (2006). Selective depletion of activated T Cells by recombinant immunotoxin containing anti-CTLA-4 single-chain fragment of variable antibody and N-terminal fragment of perforin. Transplantation Proceedings, 38, 2151-2153.
25. Hagemeyer, C. E., von Zur, M. C., Von Elverfeldt, D., & Peter, K. (2009). Single-chain antibodies as diagnostic tools and therapeutic agents. Thrombosis and Haemostasis, 101, 1012-1019.
26. Oršolić, N. (2012). Bee venom in cancer therapy. Cancer Metastasis Reviews, 31, 173-194.